Back to the article

HealthRX.com · Printable lab tracker

Rybelsus kidney and glucose lab tracker

Track the kidney and glucose results that matter on Rybelsus with chronic kidney disease: your baseline, each new eGFR, UACR and HbA1c, the label's kidney points, and the sick-day signs that should prompt a call.

Companion to “Rybelsus Dosing in Renal Impairment: What the Evidence Actually Shows” · healthrx.com/rybelsus/renal-impairment · Facts checked 2026-10-18

Starting point

eGFR and date
Urine albumin-to-creatinine ratio (UACR) and date
HbA1c and date
Dialysisnone, haemodialysis or peritoneal
Other diabetes medicinesnote any insulin or sulfonylurea

Results over time

DateeGFRCreatinineUACRHbA1cRybelsus doseNotes

Kidney points from the label and its studies

  • The recommended dose is the same at every level of kidney function, including end-stage disease, where semaglutide levels showed no clinically relevant change.[1]
  • Effectiveness was tested in 324 adults with eGFR 30 to 59 over 26 weeks (PIONEER 5).[1]
  • In the kidney drug-level study, haemodialysis did not affect semaglutide levels.[2]
  • Kidney function should be checked when side effects could cause fluid loss, especially while starting or increasing the dose.[1]

Call your prescriber promptly for

  • Vomiting, diarrhea or nausea that stops you keeping fluids down: kidney injury, sometimes needing dialysis, has been reported in people taking semaglutide.[1]
  • Severe abdominal pain that may spread to the back, with or without nausea or vomiting.[1]

For your prescriber or nephrologist

  1. How often should my eGFR and UACR be checked while I start Rybelsus?
  2. On sick days with vomiting or diarrhea, should I pause Rybelsus or any kidney medicines?
  3. Would injectable semaglutide suit my kidney goals better than tablets?
  4. Which of my morning medicines need moving to after the 30-minute wait?
Sources for the facts on this sheet
  1. Novo Nordisk, via DailyMed. Rybelsus (semaglutide) tablets and Ozempic (semaglutide) tablets, for oral use: prescribing information and Medication Guide. Effective 2026-01-30. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
  2. Granhall C, Søndergaard FL, Thomsen M, Anderson TW. Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment. Clin Pharmacokinet 2018. PMID 29623579. https://pubmed.ncbi.nlm.nih.gov/29623579/

This sheet records information for a conversation with your prescriber or pharmacist. It does not replace their instructions or the medication's prescribing information.